Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-05-09

AUTHORS

Gagik R. Galstyan, Amir Tirosh, Hernando Vargas-Uricoechea, Maria Aileen Mabunay, Mathieu Coudert, Mubarak Naqvi, Valerie Pilorget, Niaz Khan

ABSTRACT

IntroductionThe clinical benefits of insulin glargine 300 U/mL (Gla-300) have been confirmed in randomised clinical trials (EDITION programme and BRIGHT) and real-world studies in the USA and Western Europe. ATOS evaluated the real-world effectiveness and safety of Gla-300 in wider geographic regions (Asia, the Middle East, North Africa, Latin America and Eastern Europe).MethodsThis prospective observational, international study enrolled adults (≥ 18 years) with type 2 diabetes mellitus (T2DM) uncontrolled [haemoglobin A1c (HbA1c) > 7% to ≤ 11%] on one or more oral anti-hyperglycaemic drugs (OADs) who had been advised by their treating physician to add Gla-300 to their existing treatment. The primary endpoint was achievement of a pre-defined individualised HbA1c target at month 6.ResultsOf the 4550 participants included, 4422 (51.8% female) were eligible for assessment. The mean ± standard deviation (SD) age was 57.2 ± 10.8 years, duration of diabetes was 10.2 ± 6.2 years and baseline HbA1c was 9.28 ± 1.0%. The proportion of participants reaching their individualised glycaemic target was 25.2% [95% confidence interval (CI) 23.8–26.6%] at month 6 and 44.5% (95% CI 42.9–46.1%) at month 12. At months 6 and 12, reductions were observed in HbA1c (−1.50% and −1.87%) and fasting plasma glucose (−3.42 and −3.94 mmol/L). Hypoglycaemia incidence was low, and body weight change was minimal. Adverse events were reported in 283 (6.4%) participants, with 57 (1.3%) experiencing serious adverse events.ConclusionIn a real-world setting, initiation of Gla-300 in people with T2DM uncontrolled on OADs resulted in improved glycaemic control and low rates of hypoglycaemia with minimal weight change.Trial RegistrationClinicaltrials.gov number NCT03703869. More... »

PAGES

1187-1202

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-022-01266-4

DOI

http://dx.doi.org/10.1007/s13300-022-01266-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147731740

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35532858


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Endocrinology Research Centre of Health Care Ministry of Russian Federation, Dmitriya Ulyanova, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465364.6", 
          "name": [
            "Endocrinology Research Centre of Health Care Ministry of Russian Federation, Dmitriya Ulyanova, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Galstyan", 
        "givenName": "Gagik R.", 
        "id": "sg:person.014547532627.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014547532627.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel", 
          "id": "http://www.grid.ac/institutes/grid.12136.37", 
          "name": [
            "Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tirosh", 
        "givenName": "Amir", 
        "id": "sg:person.01363242403.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363242403.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayan-Cauca, Colombia", 
          "id": "http://www.grid.ac/institutes/grid.412186.8", 
          "name": [
            "Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayan-Cauca, Colombia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vargas-Uricoechea", 
        "givenName": "Hernando", 
        "id": "sg:person.0666260352.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666260352.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Singapore, Singapore", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Sanofi, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mabunay", 
        "givenName": "Maria Aileen", 
        "id": "sg:person.014000313025.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014000313025.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coudert", 
        "givenName": "Mathieu", 
        "id": "sg:person.016236166301.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016236166301.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Mumbai, India", 
          "id": "http://www.grid.ac/institutes/grid.497468.0", 
          "name": [
            "Sanofi, Mumbai, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naqvi", 
        "givenName": "Mubarak", 
        "id": "sg:person.011123407075.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011123407075.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Sanofi, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pilorget", 
        "givenName": "Valerie", 
        "id": "sg:person.0625112120.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625112120.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Imperial College London Diabetes Centre, Al Ain, United Arab Emirates", 
          "id": "http://www.grid.ac/institutes/grid.488461.7", 
          "name": [
            "Imperial College London Diabetes Centre, Al Ain, United Arab Emirates"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Khan", 
        "givenName": "Niaz", 
        "id": "sg:person.012512701733.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012512701733.99"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11892-018-1002-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103472007", 
          "https://doi.org/10.1007/s11892-018-1002-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40618-014-0069-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004817237", 
          "https://doi.org/10.1007/s40618-014-0069-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-0568-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112140157", 
          "https://doi.org/10.1007/s13300-019-0568-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-09", 
    "datePublishedReg": "2022-05-09", 
    "description": "IntroductionThe clinical benefits of insulin glargine 300\u00a0U/mL (Gla-300) have been confirmed in randomised clinical trials (EDITION programme and BRIGHT) and real-world studies in the USA and Western Europe. ATOS evaluated the real-world effectiveness and safety of Gla-300 in wider geographic regions (Asia, the Middle East, North Africa, Latin America and Eastern Europe).MethodsThis prospective observational, international study enrolled adults (\u2265\u200918\u00a0years) with type 2 diabetes mellitus (T2DM) uncontrolled [haemoglobin A1c (HbA1c)\u2009>\u20097% to\u2009\u2264\u200911%] on\u2009one or more oral anti-hyperglycaemic drugs (OADs) who had been advised by their treating physician to add Gla-300 to their existing treatment. The primary endpoint was achievement of a pre-defined individualised HbA1c target at month 6.ResultsOf the 4550 participants included, 4422 (51.8% female) were eligible for assessment. The mean\u2009\u00b1\u2009standard deviation (SD) age was 57.2\u2009\u00b1\u200910.8\u00a0years, duration of diabetes was 10.2\u2009\u00b1\u20096.2\u00a0years and baseline HbA1c was 9.28\u2009\u00b1\u20091.0%. The proportion of participants reaching their individualised glycaemic target was 25.2% [95% confidence interval (CI) 23.8\u201326.6%] at month 6 and 44.5% (95% CI 42.9\u201346.1%) at month 12. At months 6 and 12, reductions were observed in HbA1c (\u22121.50% and\u2009\u22121.87%) and fasting plasma glucose (\u22123.42 and\u2009\u22123.94\u00a0mmol/L). Hypoglycaemia incidence was low, and body weight change was minimal. Adverse events were reported in 283 (6.4%) participants, with 57 (1.3%) experiencing serious adverse events.ConclusionIn a real-world setting, initiation of Gla-300 in people with T2DM uncontrolled on OADs resulted in improved glycaemic control and low rates of hypoglycaemia with minimal weight change.Trial RegistrationClinicaltrials.gov number NCT03703869.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-022-01266-4", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "oral anti-hyperglycaemic drugs", 
      "Gla-300", 
      "month 6", 
      "adverse events", 
      "insulin glargine 300 U/mL", 
      "glargine 300 U/mL", 
      "type 2 diabetes mellitus", 
      "duration of diabetes", 
      "insulin-na\u00efve people", 
      "weight change", 
      "serious adverse events", 
      "insulin glargine 300", 
      "improved glycaemic control", 
      "standard deviation age", 
      "real-world effectiveness", 
      "proportion of participants", 
      "anti-hyperglycaemic drugs", 
      "real-world study", 
      "body weight changes", 
      "minimal weight change", 
      "glycaemic targets", 
      "primary endpoint", 
      "baseline HbA1c", 
      "glargine 300", 
      "hypoglycaemia incidence", 
      "glycaemic control", 
      "diabetes mellitus", 
      "deviation age", 
      "month 12", 
      "clinical benefit", 
      "World Effectiveness", 
      "plasma glucose", 
      "clinical trials", 
      "type 2", 
      "real-world setting", 
      "HbA1c", 
      "lower rates", 
      "international studies", 
      "participants", 
      "safety", 
      "MethodsThis", 
      "mellitus", 
      "T2DM", 
      "hypoglycaemia", 
      "geographic regions", 
      "diabetes", 
      "ConclusionIn", 
      "years", 
      "incidence", 
      "physicians", 
      "trials", 
      "endpoint", 
      "study", 
      "drugs", 
      "adults", 
      "target", 
      "age", 
      "treatment", 
      "duration", 
      "glucose", 
      "events", 
      "people", 
      "mL", 
      "changes", 
      "initiation", 
      "proportion", 
      "setting", 
      "assessment", 
      "control", 
      "effectiveness", 
      "benefits", 
      "rate", 
      "reduction", 
      "ATOS", 
      "wide geographic regions", 
      "USA", 
      "region", 
      "Western Europe", 
      "Europe", 
      "achievement"
    ], 
    "name": "Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Na\u00efve People with Type 2 Diabetes: the ATOS Study", 
    "pagination": "1187-1202", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147731740"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-022-01266-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35532858"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-022-01266-4", 
      "https://app.dimensions.ai/details/publication/pub.1147731740"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_942.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-022-01266-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01266-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01266-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01266-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01266-4'


 

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      21 PREDICATES      109 URIs      97 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-022-01266-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1117
4 schema:author N88eac79980b64a49bcba496c8ebdd358
5 schema:citation sg:pub.10.1007/s11892-018-1002-8
6 sg:pub.10.1007/s13300-019-0568-8
7 sg:pub.10.1007/s40618-014-0069-6
8 schema:datePublished 2022-05-09
9 schema:datePublishedReg 2022-05-09
10 schema:description IntroductionThe clinical benefits of insulin glargine 300 U/mL (Gla-300) have been confirmed in randomised clinical trials (EDITION programme and BRIGHT) and real-world studies in the USA and Western Europe. ATOS evaluated the real-world effectiveness and safety of Gla-300 in wider geographic regions (Asia, the Middle East, North Africa, Latin America and Eastern Europe).MethodsThis prospective observational, international study enrolled adults (≥ 18 years) with type 2 diabetes mellitus (T2DM) uncontrolled [haemoglobin A1c (HbA1c) > 7% to ≤ 11%] on one or more oral anti-hyperglycaemic drugs (OADs) who had been advised by their treating physician to add Gla-300 to their existing treatment. The primary endpoint was achievement of a pre-defined individualised HbA1c target at month 6.ResultsOf the 4550 participants included, 4422 (51.8% female) were eligible for assessment. The mean ± standard deviation (SD) age was 57.2 ± 10.8 years, duration of diabetes was 10.2 ± 6.2 years and baseline HbA1c was 9.28 ± 1.0%. The proportion of participants reaching their individualised glycaemic target was 25.2% [95% confidence interval (CI) 23.8–26.6%] at month 6 and 44.5% (95% CI 42.9–46.1%) at month 12. At months 6 and 12, reductions were observed in HbA1c (−1.50% and −1.87%) and fasting plasma glucose (−3.42 and −3.94 mmol/L). Hypoglycaemia incidence was low, and body weight change was minimal. Adverse events were reported in 283 (6.4%) participants, with 57 (1.3%) experiencing serious adverse events.ConclusionIn a real-world setting, initiation of Gla-300 in people with T2DM uncontrolled on OADs resulted in improved glycaemic control and low rates of hypoglycaemia with minimal weight change.Trial RegistrationClinicaltrials.gov number NCT03703869.
11 schema:genre article
12 schema:isAccessibleForFree true
13 schema:isPartOf Nd33f2088426243dfbc90e8cee478666a
14 Nd5bd2ac424724d71b9f35ffafcae9c45
15 sg:journal.1044057
16 schema:keywords ATOS
17 ConclusionIn
18 Europe
19 Gla-300
20 HbA1c
21 MethodsThis
22 T2DM
23 USA
24 Western Europe
25 World Effectiveness
26 achievement
27 adults
28 adverse events
29 age
30 anti-hyperglycaemic drugs
31 assessment
32 baseline HbA1c
33 benefits
34 body weight changes
35 changes
36 clinical benefit
37 clinical trials
38 control
39 deviation age
40 diabetes
41 diabetes mellitus
42 drugs
43 duration
44 duration of diabetes
45 effectiveness
46 endpoint
47 events
48 geographic regions
49 glargine 300
50 glargine 300 U/mL
51 glucose
52 glycaemic control
53 glycaemic targets
54 hypoglycaemia
55 hypoglycaemia incidence
56 improved glycaemic control
57 incidence
58 initiation
59 insulin glargine 300
60 insulin glargine 300 U/mL
61 insulin-naïve people
62 international studies
63 lower rates
64 mL
65 mellitus
66 minimal weight change
67 month 12
68 month 6
69 oral anti-hyperglycaemic drugs
70 participants
71 people
72 physicians
73 plasma glucose
74 primary endpoint
75 proportion
76 proportion of participants
77 rate
78 real-world effectiveness
79 real-world setting
80 real-world study
81 reduction
82 region
83 safety
84 serious adverse events
85 setting
86 standard deviation age
87 study
88 target
89 treatment
90 trials
91 type 2
92 type 2 diabetes mellitus
93 weight change
94 wide geographic regions
95 years
96 schema:name Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study
97 schema:pagination 1187-1202
98 schema:productId N936ae09643264bc0aeab9acf6188db1d
99 Nbfaed01329ae4ccd81b48862a19537fc
100 Nf3ca4c7d9b244883af80edc755c4e14f
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147731740
102 https://doi.org/10.1007/s13300-022-01266-4
103 schema:sdDatePublished 2022-08-04T17:12
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N191619eef71f46ca908e3370d395da5f
106 schema:url https://doi.org/10.1007/s13300-022-01266-4
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N0d411a93b26e4dc3b57f14cd29b51d90 rdf:first sg:person.012512701733.99
111 rdf:rest rdf:nil
112 N191619eef71f46ca908e3370d395da5f schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 N3f4984fa45fd4395a7d61c6c1d0a29e5 rdf:first sg:person.014000313025.34
115 rdf:rest Nf04422d2a8184f97b0a0e2617c8f9eec
116 N7773a63890f849eaa08d17091effc3f1 rdf:first sg:person.0625112120.31
117 rdf:rest N0d411a93b26e4dc3b57f14cd29b51d90
118 N809fbfdaec164da2830861768b0d3f31 rdf:first sg:person.011123407075.15
119 rdf:rest N7773a63890f849eaa08d17091effc3f1
120 N88eac79980b64a49bcba496c8ebdd358 rdf:first sg:person.014547532627.14
121 rdf:rest Nb6e2b012d80b4b9ab49c6df1080a4537
122 N936ae09643264bc0aeab9acf6188db1d schema:name pubmed_id
123 schema:value 35532858
124 rdf:type schema:PropertyValue
125 Nb6e2b012d80b4b9ab49c6df1080a4537 rdf:first sg:person.01363242403.79
126 rdf:rest Nc3a57981f5ac4585a5b45bb1a6289ed6
127 Nbfaed01329ae4ccd81b48862a19537fc schema:name doi
128 schema:value 10.1007/s13300-022-01266-4
129 rdf:type schema:PropertyValue
130 Nc3a57981f5ac4585a5b45bb1a6289ed6 rdf:first sg:person.0666260352.62
131 rdf:rest N3f4984fa45fd4395a7d61c6c1d0a29e5
132 Nd33f2088426243dfbc90e8cee478666a schema:volumeNumber 13
133 rdf:type schema:PublicationVolume
134 Nd5bd2ac424724d71b9f35ffafcae9c45 schema:issueNumber 6
135 rdf:type schema:PublicationIssue
136 Nf04422d2a8184f97b0a0e2617c8f9eec rdf:first sg:person.016236166301.55
137 rdf:rest N809fbfdaec164da2830861768b0d3f31
138 Nf3ca4c7d9b244883af80edc755c4e14f schema:name dimensions_id
139 schema:value pub.1147731740
140 rdf:type schema:PropertyValue
141 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
142 schema:name Medical and Health Sciences
143 rdf:type schema:DefinedTerm
144 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
145 schema:name Clinical Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
148 schema:name Public Health and Health Services
149 rdf:type schema:DefinedTerm
150 sg:journal.1044057 schema:issn 1869-6953
151 1869-6961
152 schema:name Diabetes Therapy
153 schema:publisher Springer Nature
154 rdf:type schema:Periodical
155 sg:person.011123407075.15 schema:affiliation grid-institutes:grid.497468.0
156 schema:familyName Naqvi
157 schema:givenName Mubarak
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011123407075.15
159 rdf:type schema:Person
160 sg:person.012512701733.99 schema:affiliation grid-institutes:grid.488461.7
161 schema:familyName Khan
162 schema:givenName Niaz
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012512701733.99
164 rdf:type schema:Person
165 sg:person.01363242403.79 schema:affiliation grid-institutes:grid.12136.37
166 schema:familyName Tirosh
167 schema:givenName Amir
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363242403.79
169 rdf:type schema:Person
170 sg:person.014000313025.34 schema:affiliation grid-institutes:None
171 schema:familyName Mabunay
172 schema:givenName Maria Aileen
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014000313025.34
174 rdf:type schema:Person
175 sg:person.014547532627.14 schema:affiliation grid-institutes:grid.465364.6
176 schema:familyName Galstyan
177 schema:givenName Gagik R.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014547532627.14
179 rdf:type schema:Person
180 sg:person.016236166301.55 schema:affiliation grid-institutes:grid.417924.d
181 schema:familyName Coudert
182 schema:givenName Mathieu
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016236166301.55
184 rdf:type schema:Person
185 sg:person.0625112120.31 schema:affiliation grid-institutes:grid.417924.d
186 schema:familyName Pilorget
187 schema:givenName Valerie
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625112120.31
189 rdf:type schema:Person
190 sg:person.0666260352.62 schema:affiliation grid-institutes:grid.412186.8
191 schema:familyName Vargas-Uricoechea
192 schema:givenName Hernando
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666260352.62
194 rdf:type schema:Person
195 sg:pub.10.1007/s11892-018-1002-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103472007
196 https://doi.org/10.1007/s11892-018-1002-8
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/s13300-019-0568-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112140157
199 https://doi.org/10.1007/s13300-019-0568-8
200 rdf:type schema:CreativeWork
201 sg:pub.10.1007/s40618-014-0069-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004817237
202 https://doi.org/10.1007/s40618-014-0069-6
203 rdf:type schema:CreativeWork
204 grid-institutes:None schema:alternateName Sanofi, Singapore, Singapore
205 schema:name Sanofi, Singapore, Singapore
206 rdf:type schema:Organization
207 grid-institutes:grid.12136.37 schema:alternateName Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
208 schema:name Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
209 rdf:type schema:Organization
210 grid-institutes:grid.412186.8 schema:alternateName Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayan-Cauca, Colombia
211 schema:name Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayan-Cauca, Colombia
212 rdf:type schema:Organization
213 grid-institutes:grid.417924.d schema:alternateName Sanofi, Paris, France
214 schema:name Sanofi, Paris, France
215 rdf:type schema:Organization
216 grid-institutes:grid.465364.6 schema:alternateName Endocrinology Research Centre of Health Care Ministry of Russian Federation, Dmitriya Ulyanova, Moscow, Russia
217 schema:name Endocrinology Research Centre of Health Care Ministry of Russian Federation, Dmitriya Ulyanova, Moscow, Russia
218 rdf:type schema:Organization
219 grid-institutes:grid.488461.7 schema:alternateName Imperial College London Diabetes Centre, Al Ain, United Arab Emirates
220 schema:name Imperial College London Diabetes Centre, Al Ain, United Arab Emirates
221 rdf:type schema:Organization
222 grid-institutes:grid.497468.0 schema:alternateName Sanofi, Mumbai, India
223 schema:name Sanofi, Mumbai, India
224 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...